nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C8—Sorafenib—liver cancer	0.119	0.217	CbGbCtD
Levomilnacipran—CYP2C19—Sorafenib—liver cancer	0.0999	0.182	CbGbCtD
Levomilnacipran—ABCB1—Sorafenib—liver cancer	0.0806	0.147	CbGbCtD
Levomilnacipran—CYP2D6—Sorafenib—liver cancer	0.0759	0.139	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—liver cancer	0.0489	0.0892	CbGbCtD
Levomilnacipran—CYP3A4—Sorafenib—liver cancer	0.0483	0.0881	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—liver cancer	0.0461	0.0841	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—liver cancer	0.0293	0.0535	CbGbCtD
Levomilnacipran—Hypertensive crisis—Sorafenib—liver cancer	0.013	0.0604	CcSEcCtD
Levomilnacipran—Endocrine disorder—Sorafenib—liver cancer	0.00436	0.0202	CcSEcCtD
Levomilnacipran—Proteinuria—Sorafenib—liver cancer	0.00411	0.0191	CcSEcCtD
Levomilnacipran—Rhabdomyolysis—Sorafenib—liver cancer	0.00408	0.019	CcSEcCtD
Levomilnacipran—Protein urine present—Sorafenib—liver cancer	0.00405	0.0188	CcSEcCtD
Levomilnacipran—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.004	0.0186	CcSEcCtD
Levomilnacipran—Blood pressure increased—Sorafenib—liver cancer	0.00361	0.0168	CcSEcCtD
Levomilnacipran—Renal failure acute—Sorafenib—liver cancer	0.00284	0.0132	CcSEcCtD
Levomilnacipran—Hyponatraemia—Sorafenib—liver cancer	0.00263	0.0122	CcSEcCtD
Levomilnacipran—Dry skin—Sorafenib—liver cancer	0.0024	0.0112	CcSEcCtD
Levomilnacipran—Breast disorder—Sorafenib—liver cancer	0.00237	0.011	CcSEcCtD
Levomilnacipran—Neutropenia—Sorafenib—liver cancer	0.00212	0.00984	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Sorafenib—liver cancer	0.00209	0.00969	CcSEcCtD
Levomilnacipran—Weight decreased—Sorafenib—liver cancer	0.00205	0.00952	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.002	0.0093	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Sorafenib—liver cancer	0.00191	0.00887	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Sorafenib—liver cancer	0.00179	0.00832	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Sorafenib—liver cancer	0.00178	0.00827	CcSEcCtD
Levomilnacipran—Urethral disorder—Sorafenib—liver cancer	0.00178	0.00825	CcSEcCtD
Levomilnacipran—Erythema multiforme—Sorafenib—liver cancer	0.00172	0.00796	CcSEcCtD
Levomilnacipran—Cardiac disorder—Sorafenib—liver cancer	0.00168	0.00781	CcSEcCtD
Levomilnacipran—Flushing—Sorafenib—liver cancer	0.00168	0.00781	CcSEcCtD
Levomilnacipran—Angiopathy—Sorafenib—liver cancer	0.00165	0.00764	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Sorafenib—liver cancer	0.00163	0.00759	CcSEcCtD
Levomilnacipran—Mental disorder—Sorafenib—liver cancer	0.00159	0.00738	CcSEcCtD
Levomilnacipran—Malnutrition—Sorafenib—liver cancer	0.00158	0.00733	CcSEcCtD
Levomilnacipran—Delirium—Epirubicin—liver cancer	0.00155	0.0072	CcSEcCtD
Levomilnacipran—Dysgeusia—Sorafenib—liver cancer	0.00155	0.00718	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Epirubicin—liver cancer	0.00148	0.00686	CcSEcCtD
Levomilnacipran—Delirium—Doxorubicin—liver cancer	0.00144	0.00667	CcSEcCtD
Levomilnacipran—Syncope—Sorafenib—liver cancer	0.00142	0.00657	CcSEcCtD
Levomilnacipran—Leukopenia—Sorafenib—liver cancer	0.00141	0.00656	CcSEcCtD
Levomilnacipran—Loss of consciousness—Sorafenib—liver cancer	0.00139	0.00644	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Doxorubicin—liver cancer	0.00137	0.00635	CcSEcCtD
Levomilnacipran—Hypertension—Sorafenib—liver cancer	0.00136	0.00633	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00134	0.0062	CcSEcCtD
Levomilnacipran—Dry mouth—Sorafenib—liver cancer	0.00131	0.0061	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Epirubicin—liver cancer	0.0013	0.00605	CcSEcCtD
Levomilnacipran—Cystitis—Epirubicin—liver cancer	0.00129	0.00598	CcSEcCtD
Levomilnacipran—Infection—Sorafenib—liver cancer	0.00128	0.00594	CcSEcCtD
Levomilnacipran—Shock—Sorafenib—liver cancer	0.00127	0.00589	CcSEcCtD
Levomilnacipran—Nervous system disorder—Sorafenib—liver cancer	0.00126	0.00587	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Sorafenib—liver cancer	0.00126	0.00586	CcSEcCtD
Levomilnacipran—Skin disorder—Sorafenib—liver cancer	0.00125	0.00581	CcSEcCtD
Levomilnacipran—Dry eye—Epirubicin—liver cancer	0.00123	0.00572	CcSEcCtD
Levomilnacipran—Anorexia—Sorafenib—liver cancer	0.00123	0.0057	CcSEcCtD
Levomilnacipran—Bladder pain—Epirubicin—liver cancer	0.00121	0.0056	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Doxorubicin—liver cancer	0.00121	0.0056	CcSEcCtD
Levomilnacipran—Cystitis—Doxorubicin—liver cancer	0.00119	0.00554	CcSEcCtD
Levomilnacipran—Dyspnoea—Sorafenib—liver cancer	0.00115	0.00533	CcSEcCtD
Levomilnacipran—Dry eye—Doxorubicin—liver cancer	0.00114	0.0053	CcSEcCtD
Levomilnacipran—Dyspepsia—Sorafenib—liver cancer	0.00113	0.00527	CcSEcCtD
Levomilnacipran—Decreased appetite—Sorafenib—liver cancer	0.00112	0.0052	CcSEcCtD
Levomilnacipran—Bladder pain—Doxorubicin—liver cancer	0.00112	0.00518	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Sorafenib—liver cancer	0.00111	0.00516	CcSEcCtD
Levomilnacipran—Fatigue—Sorafenib—liver cancer	0.00111	0.00516	CcSEcCtD
Levomilnacipran—Constipation—Sorafenib—liver cancer	0.0011	0.00512	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Sorafenib—liver cancer	0.00105	0.00489	CcSEcCtD
Levomilnacipran—Renal failure acute—Epirubicin—liver cancer	0.00105	0.00487	CcSEcCtD
Levomilnacipran—Hot flush—Epirubicin—liver cancer	0.00104	0.00481	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Epirubicin—liver cancer	0.00103	0.00477	CcSEcCtD
Levomilnacipran—Urticaria—Sorafenib—liver cancer	0.00102	0.00475	CcSEcCtD
Levomilnacipran—Abdominal pain—Sorafenib—liver cancer	0.00102	0.00473	CcSEcCtD
Levomilnacipran—Body temperature increased—Sorafenib—liver cancer	0.00102	0.00473	CcSEcCtD
Levomilnacipran—Hyponatraemia—Epirubicin—liver cancer	0.000973	0.00452	CcSEcCtD
Levomilnacipran—Renal failure acute—Doxorubicin—liver cancer	0.000971	0.00451	CcSEcCtD
Levomilnacipran—Hot flush—Doxorubicin—liver cancer	0.000958	0.00445	CcSEcCtD
Levomilnacipran—Migraine—Epirubicin—liver cancer	0.000954	0.00443	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Doxorubicin—liver cancer	0.00095	0.00441	CcSEcCtD
Levomilnacipran—Hypersensitivity—Sorafenib—liver cancer	0.000949	0.00441	CcSEcCtD
Levomilnacipran—Asthenia—Sorafenib—liver cancer	0.000925	0.00429	CcSEcCtD
Levomilnacipran—Pruritus—Sorafenib—liver cancer	0.000912	0.00423	CcSEcCtD
Levomilnacipran—Hyponatraemia—Doxorubicin—liver cancer	0.0009	0.00418	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Epirubicin—liver cancer	0.000895	0.00415	CcSEcCtD
Levomilnacipran—Dry skin—Epirubicin—liver cancer	0.000888	0.00412	CcSEcCtD
Levomilnacipran—Migraine—Doxorubicin—liver cancer	0.000883	0.0041	CcSEcCtD
Levomilnacipran—Diarrhoea—Sorafenib—liver cancer	0.000882	0.00409	CcSEcCtD
Levomilnacipran—Breast disorder—Epirubicin—liver cancer	0.000876	0.00406	CcSEcCtD
Levomilnacipran—Dizziness—Sorafenib—liver cancer	0.000852	0.00396	CcSEcCtD
Levomilnacipran—Abdominal distension—Epirubicin—liver cancer	0.000843	0.00391	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Doxorubicin—liver cancer	0.000828	0.00384	CcSEcCtD
Levomilnacipran—Dry skin—Doxorubicin—liver cancer	0.000822	0.00382	CcSEcCtD
Levomilnacipran—Vomiting—Sorafenib—liver cancer	0.000819	0.0038	CcSEcCtD
Levomilnacipran—Angina pectoris—Epirubicin—liver cancer	0.000816	0.00379	CcSEcCtD
Levomilnacipran—Rash—Sorafenib—liver cancer	0.000813	0.00377	CcSEcCtD
Levomilnacipran—Dermatitis—Sorafenib—liver cancer	0.000812	0.00377	CcSEcCtD
Levomilnacipran—Breast disorder—Doxorubicin—liver cancer	0.00081	0.00376	CcSEcCtD
Levomilnacipran—Headache—Sorafenib—liver cancer	0.000807	0.00375	CcSEcCtD
Levomilnacipran—Dysuria—Epirubicin—liver cancer	0.000783	0.00364	CcSEcCtD
Levomilnacipran—Neutropenia—Epirubicin—liver cancer	0.000783	0.00364	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—liver cancer	0.00078	0.00362	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Epirubicin—liver cancer	0.000778	0.00361	CcSEcCtD
Levomilnacipran—Pollakiuria—Epirubicin—liver cancer	0.000774	0.00359	CcSEcCtD
Levomilnacipran—Nausea—Sorafenib—liver cancer	0.000765	0.00355	CcSEcCtD
Levomilnacipran—Weight decreased—Epirubicin—liver cancer	0.000758	0.00352	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—liver cancer	0.000755	0.0035	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00074	0.00344	CcSEcCtD
Levomilnacipran—Urinary tract infection—Epirubicin—liver cancer	0.000726	0.00337	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—liver cancer	0.000725	0.00336	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—liver cancer	0.000725	0.00336	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00072	0.00334	CcSEcCtD
Levomilnacipran—Pollakiuria—Doxorubicin—liver cancer	0.000716	0.00332	CcSEcCtD
Levomilnacipran—Haematuria—Epirubicin—liver cancer	0.000712	0.00331	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Epirubicin—liver cancer	0.000706	0.00328	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—liver cancer	0.000701	0.00325	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000685	0.00318	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—liver cancer	0.000672	0.00312	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—liver cancer	0.00067	0.00311	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—liver cancer	0.000667	0.0031	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—liver cancer	0.000662	0.00307	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—liver cancer	0.00066	0.00307	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—liver cancer	0.000659	0.00306	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—liver cancer	0.000659	0.00306	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—liver cancer	0.000657	0.00305	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—liver cancer	0.000653	0.00303	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—liver cancer	0.000634	0.00294	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—liver cancer	0.000626	0.00291	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—liver cancer	0.000622	0.00289	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—liver cancer	0.000622	0.00289	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—liver cancer	0.00062	0.00288	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—liver cancer	0.000617	0.00286	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—liver cancer	0.000613	0.00284	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—liver cancer	0.000611	0.00284	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—liver cancer	0.00061	0.00283	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—liver cancer	0.000608	0.00282	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—liver cancer	0.000608	0.00282	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—liver cancer	0.000604	0.0028	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—liver cancer	0.000601	0.00279	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—liver cancer	0.000587	0.00273	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—liver cancer	0.000586	0.00272	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—liver cancer	0.000584	0.00271	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—liver cancer	0.00058	0.00269	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—liver cancer	0.000576	0.00267	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—liver cancer	0.000576	0.00267	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—liver cancer	0.000575	0.00267	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—liver cancer	0.000573	0.00266	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—liver cancer	0.000571	0.00265	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—liver cancer	0.000563	0.00261	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—liver cancer	0.000559	0.0026	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—liver cancer	0.000557	0.00258	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—liver cancer	0.00055	0.00255	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—liver cancer	0.000543	0.00252	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—liver cancer	0.00054	0.00251	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—liver cancer	0.000536	0.00249	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—liver cancer	0.000532	0.00247	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—liver cancer	0.00053	0.00246	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—liver cancer	0.000529	0.00245	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—liver cancer	0.000523	0.00243	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—liver cancer	0.000522	0.00242	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—liver cancer	0.000516	0.00239	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—liver cancer	0.000513	0.00238	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—liver cancer	0.000509	0.00236	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—liver cancer	0.000506	0.00235	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—liver cancer	0.000504	0.00234	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—liver cancer	0.000497	0.00231	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—liver cancer	0.000496	0.0023	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—liver cancer	0.000495	0.0023	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000493	0.00229	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—liver cancer	0.000486	0.00226	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—liver cancer	0.000484	0.00225	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—liver cancer	0.000483	0.00224	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—liver cancer	0.000477	0.00222	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—liver cancer	0.000475	0.0022	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—liver cancer	0.000473	0.0022	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—liver cancer	0.000469	0.00218	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—liver cancer	0.000468	0.00217	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—liver cancer	0.000467	0.00217	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—liver cancer	0.000466	0.00216	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—liver cancer	0.000466	0.00216	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—liver cancer	0.000465	0.00216	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—liver cancer	0.000463	0.00215	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—liver cancer	0.00046	0.00214	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—liver cancer	0.00046	0.00213	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—liver cancer	0.000458	0.00213	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000457	0.00212	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—liver cancer	0.000454	0.00211	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—liver cancer	0.00045	0.00209	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—liver cancer	0.000445	0.00207	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—liver cancer	0.000438	0.00203	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—liver cancer	0.000434	0.00201	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—liver cancer	0.000432	0.00201	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—liver cancer	0.000431	0.002	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—liver cancer	0.000431	0.002	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—liver cancer	0.00043	0.002	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—liver cancer	0.000428	0.00199	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—liver cancer	0.000428	0.00199	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—liver cancer	0.000426	0.00198	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—liver cancer	0.000425	0.00197	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—liver cancer	0.000423	0.00197	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—liver cancer	0.00042	0.00195	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—liver cancer	0.000419	0.00195	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—liver cancer	0.000414	0.00192	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—liver cancer	0.000412	0.00191	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—liver cancer	0.000411	0.00191	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—liver cancer	0.000411	0.00191	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—liver cancer	0.000407	0.00189	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—liver cancer	0.000399	0.00185	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—liver cancer	0.000396	0.00184	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—liver cancer	0.000393	0.00182	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—liver cancer	0.000392	0.00182	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—liver cancer	0.000389	0.00181	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—liver cancer	0.000388	0.0018	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—liver cancer	0.000383	0.00178	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00038	0.00177	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—liver cancer	0.00038	0.00176	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—liver cancer	0.000378	0.00176	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—liver cancer	0.000377	0.00175	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—liver cancer	0.000376	0.00175	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—liver cancer	0.000376	0.00175	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—liver cancer	0.00036	0.00167	CcSEcCtD
Levomilnacipran—Hypersensitivity—Epirubicin—liver cancer	0.000351	0.00163	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—liver cancer	0.00035	0.00163	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—liver cancer	0.000348	0.00162	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—liver cancer	0.000348	0.00162	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—liver cancer	0.000342	0.00159	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—liver cancer	0.000337	0.00156	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—liver cancer	0.000326	0.00151	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—liver cancer	0.000325	0.00151	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—liver cancer	0.000316	0.00147	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—liver cancer	0.000315	0.00146	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—liver cancer	0.000312	0.00145	CcSEcCtD
Levomilnacipran—Vomiting—Epirubicin—liver cancer	0.000303	0.00141	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—liver cancer	0.000302	0.0014	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—liver cancer	0.0003	0.00139	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—liver cancer	0.0003	0.00139	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—liver cancer	0.000298	0.00139	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—liver cancer	0.000291	0.00135	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—liver cancer	0.000283	0.00131	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—liver cancer	0.00028	0.0013	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—liver cancer	0.000278	0.00129	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—liver cancer	0.000278	0.00129	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—liver cancer	0.000276	0.00128	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—liver cancer	0.000262	0.00122	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—liver cancer	0.000123	0.000518	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTP1—liver cancer	0.00012	0.000505	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—HMOX1—liver cancer	0.000118	0.000498	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000117	0.000495	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—liver cancer	0.000116	0.000489	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000114	0.000482	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—UGDH—liver cancer	0.000114	0.00048	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000114	0.00048	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000112	0.000473	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTM1—liver cancer	0.00011	0.000464	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—liver cancer	0.000109	0.000462	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—EPT1—liver cancer	0.000107	0.000452	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TGFB1—liver cancer	0.000106	0.000448	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000104	0.000441	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP1A1—liver cancer	0.000104	0.00044	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000103	0.000435	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000102	0.00043	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—UGDH—liver cancer	0.000102	0.000429	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TAT—liver cancer	0.000101	0.000428	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000101	0.000426	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—PPARA—liver cancer	0.000101	0.000424	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—liver cancer	0.0001	0.000423	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	9.97e-05	0.000421	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—liver cancer	9.91e-05	0.000419	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—UGDH—liver cancer	9.91e-05	0.000419	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MTHFR—liver cancer	9.71e-05	0.00041	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—EPT1—liver cancer	9.55e-05	0.000403	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	9.55e-05	0.000403	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PPARA—liver cancer	9.53e-05	0.000402	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTP1—liver cancer	9.37e-05	0.000396	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—UGDH—liver cancer	9.34e-05	0.000394	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—EPT1—liver cancer	9.32e-05	0.000394	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	9.24e-05	0.00039	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TAT—liver cancer	9.05e-05	0.000382	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	8.9e-05	0.000376	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TAT—liver cancer	8.83e-05	0.000373	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—EPT1—liver cancer	8.78e-05	0.000371	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTM1—liver cancer	8.61e-05	0.000364	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.56e-05	0.000362	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	8.52e-05	0.00036	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	8.49e-05	0.000359	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TAT—liver cancer	8.32e-05	0.000352	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1A1—liver cancer	8.16e-05	0.000345	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CG—liver cancer	8.16e-05	0.000345	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	8.05e-05	0.00034	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PPARG—liver cancer	7.88e-05	0.000333	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	7.49e-05	0.000316	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ALB—liver cancer	7.47e-05	0.000315	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GGT1—liver cancer	7.46e-05	0.000315	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CD—liver cancer	7.18e-05	0.000303	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ALB—liver cancer	7.08e-05	0.000299	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CPT1B—liver cancer	6.89e-05	0.000291	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GLUL—liver cancer	6.89e-05	0.000291	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	6.86e-05	0.00029	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—RAF1—liver cancer	6.75e-05	0.000285	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	6.73e-05	0.000284	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—liver cancer	6.66e-05	0.000281	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NR1H4—liver cancer	6.65e-05	0.000281	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	6.55e-05	0.000277	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	6.53e-05	0.000276	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTA3—liver cancer	6.53e-05	0.000276	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	6.48e-05	0.000274	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	6.33e-05	0.000268	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	6.3e-05	0.000266	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CB—liver cancer	6.25e-05	0.000264	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	6.18e-05	0.000261	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CPT1B—liver cancer	6.15e-05	0.00026	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GLUL—liver cancer	6.15e-05	0.00026	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UGDH—liver cancer	6.11e-05	0.000258	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CPT1B—liver cancer	6.01e-05	0.000254	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GLUL—liver cancer	6.01e-05	0.000254	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTA4—liver cancer	5.98e-05	0.000252	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NR1H4—liver cancer	5.93e-05	0.000251	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	5.84e-05	0.000247	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTA3—liver cancer	5.83e-05	0.000246	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTA2—liver cancer	5.82e-05	0.000246	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NR1H4—liver cancer	5.79e-05	0.000245	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—EPT1—liver cancer	5.74e-05	0.000242	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	5.71e-05	0.000241	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTA3—liver cancer	5.69e-05	0.00024	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CPT1B—liver cancer	5.66e-05	0.000239	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GLUL—liver cancer	5.66e-05	0.000239	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTA1—liver cancer	5.62e-05	0.000237	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NAT2—liver cancer	5.56e-05	0.000235	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	5.48e-05	0.000231	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NR1H4—liver cancer	5.46e-05	0.00023	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TAT—liver cancer	5.44e-05	0.00023	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTA3—liver cancer	5.36e-05	0.000227	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—liver cancer	5.34e-05	0.000226	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTA4—liver cancer	5.33e-05	0.000225	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALDOB—liver cancer	5.33e-05	0.000225	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	5.25e-05	0.000222	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	5.24e-05	0.000221	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	5.21e-05	0.00022	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTA4—liver cancer	5.21e-05	0.00022	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTA2—liver cancer	5.2e-05	0.00022	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CRABP1—liver cancer	5.08e-05	0.000215	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTA2—liver cancer	5.07e-05	0.000214	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTA1—liver cancer	5.02e-05	0.000212	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NAT2—liver cancer	4.96e-05	0.000209	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTA4—liver cancer	4.91e-05	0.000207	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTA1—liver cancer	4.9e-05	0.000207	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	4.89e-05	0.000207	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	4.85e-05	0.000205	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NAT2—liver cancer	4.84e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTA2—liver cancer	4.78e-05	0.000202	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	4.77e-05	0.000201	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALDOB—liver cancer	4.75e-05	0.000201	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALDOB—liver cancer	4.64e-05	0.000196	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTA1—liver cancer	4.61e-05	0.000195	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.58e-05	0.000193	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NAT2—liver cancer	4.56e-05	0.000193	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CRABP1—liver cancer	4.54e-05	0.000192	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	4.46e-05	0.000188	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HPGDS—liver cancer	4.44e-05	0.000188	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CRABP1—liver cancer	4.43e-05	0.000187	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	4.43e-05	0.000187	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.42e-05	0.000186	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALDOB—liver cancer	4.37e-05	0.000185	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	4.31e-05	0.000182	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CRABP1—liver cancer	4.17e-05	0.000176	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.08e-05	0.000172	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.02e-05	0.00017	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.97e-05	0.000168	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HPGDS—liver cancer	3.96e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PSMD10—liver cancer	3.96e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PSMA4—liver cancer	3.96e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.94e-05	0.000166	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HPGDS—liver cancer	3.87e-05	0.000163	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GOT2—liver cancer	3.85e-05	0.000163	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—liver cancer	3.81e-05	0.000161	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CPT1B—liver cancer	3.7e-05	0.000156	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GLUL—liver cancer	3.7e-05	0.000156	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HPGDS—liver cancer	3.65e-05	0.000154	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.64e-05	0.000154	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2E1—liver cancer	3.62e-05	0.000153	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.59e-05	0.000152	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NR1H4—liver cancer	3.57e-05	0.000151	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.54e-05	0.00015	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PSMA4—liver cancer	3.53e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PSMD10—liver cancer	3.53e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA3—liver cancer	3.51e-05	0.000148	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.51e-05	0.000148	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PSMD10—liver cancer	3.45e-05	0.000146	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PSMA4—liver cancer	3.45e-05	0.000146	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GOT2—liver cancer	3.44e-05	0.000145	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYCS—liver cancer	3.39e-05	0.000143	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GOT2—liver cancer	3.36e-05	0.000142	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GGT1—liver cancer	3.32e-05	0.00014	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GOT1—liver cancer	3.32e-05	0.00014	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	3.29e-05	0.000139	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PSMD10—liver cancer	3.25e-05	0.000137	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PSMA4—liver cancer	3.25e-05	0.000137	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2E1—liver cancer	3.23e-05	0.000136	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA4—liver cancer	3.21e-05	0.000135	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GOT2—liver cancer	3.16e-05	0.000134	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2E1—liver cancer	3.15e-05	0.000133	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.13e-05	0.000132	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA2—liver cancer	3.13e-05	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—liver cancer	3.11e-05	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYCS—liver cancer	3.02e-05	0.000128	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA1—liver cancer	3.02e-05	0.000127	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—liver cancer	2.99e-05	0.000126	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NAT2—liver cancer	2.98e-05	0.000126	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	2.97e-05	0.000126	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2E1—liver cancer	2.97e-05	0.000126	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GOT1—liver cancer	2.97e-05	0.000125	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GGT1—liver cancer	2.97e-05	0.000125	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYCS—liver cancer	2.95e-05	0.000125	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HMOX1—liver cancer	2.94e-05	0.000124	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GGT1—liver cancer	2.9e-05	0.000122	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GOT1—liver cancer	2.9e-05	0.000122	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALDOB—liver cancer	2.86e-05	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYCS—liver cancer	2.78e-05	0.000117	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—liver cancer	2.74e-05	0.000116	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GOT1—liver cancer	2.73e-05	0.000115	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GGT1—liver cancer	2.73e-05	0.000115	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CRABP1—liver cancer	2.73e-05	0.000115	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—liver cancer	2.67e-05	0.000113	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HMOX1—liver cancer	2.63e-05	0.000111	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—liver cancer	2.6e-05	0.00011	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1A1—liver cancer	2.6e-05	0.00011	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMOX1—liver cancer	2.57e-05	0.000108	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—liver cancer	2.45e-05	0.000104	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—liver cancer	2.45e-05	0.000103	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—liver cancer	2.43e-05	0.000102	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMOX1—liver cancer	2.42e-05	0.000102	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—liver cancer	2.39e-05	0.000101	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HPGDS—liver cancer	2.38e-05	0.000101	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARA—liver cancer	2.38e-05	0.0001	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1A1—liver cancer	2.32e-05	9.81e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1A1—liver cancer	2.27e-05	9.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—liver cancer	2.25e-05	9.51e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—liver cancer	2.16e-05	9.14e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.14e-05	9.02e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1A1—liver cancer	2.14e-05	9.02e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PSMA4—liver cancer	2.12e-05	8.97e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PSMD10—liver cancer	2.12e-05	8.97e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARA—liver cancer	2.12e-05	8.97e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—liver cancer	2.11e-05	8.92e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARA—liver cancer	2.07e-05	8.75e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GOT2—liver cancer	2.07e-05	8.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—liver cancer	2.04e-05	8.6e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—liver cancer	1.99e-05	8.41e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARG—liver cancer	1.97e-05	8.3e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARA—liver cancer	1.95e-05	8.25e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2E1—liver cancer	1.94e-05	8.21e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.91e-05	8.06e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—liver cancer	1.82e-05	7.68e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYCS—liver cancer	1.82e-05	7.68e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CD—liver cancer	1.79e-05	7.56e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GOT1—liver cancer	1.78e-05	7.54e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GGT1—liver cancer	1.78e-05	7.54e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—liver cancer	1.78e-05	7.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALB—liver cancer	1.77e-05	7.47e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARG—liver cancer	1.76e-05	7.41e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARG—liver cancer	1.71e-05	7.23e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—liver cancer	1.67e-05	7.06e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARG—liver cancer	1.61e-05	6.82e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—liver cancer	1.6e-05	6.77e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CD—liver cancer	1.6e-05	6.75e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMOX1—liver cancer	1.58e-05	6.68e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALB—liver cancer	1.58e-05	6.67e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CB—liver cancer	1.56e-05	6.59e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CD—liver cancer	1.56e-05	6.59e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALB—liver cancer	1.54e-05	6.51e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—liver cancer	1.47e-05	6.22e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CD—liver cancer	1.47e-05	6.21e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALB—liver cancer	1.45e-05	6.13e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1A1—liver cancer	1.4e-05	5.9e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CB—liver cancer	1.39e-05	5.88e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CB—liver cancer	1.36e-05	5.74e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—liver cancer	1.3e-05	5.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CB—liver cancer	1.28e-05	5.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARA—liver cancer	1.28e-05	5.39e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—liver cancer	1.09e-05	4.62e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARG—liver cancer	1.06e-05	4.46e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CD—liver cancer	9.61e-06	4.06e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—liver cancer	9.52e-06	4.02e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALB—liver cancer	9.49e-06	4.01e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—liver cancer	8.5e-06	3.59e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CB—liver cancer	8.38e-06	3.54e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—liver cancer	8.29e-06	3.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—liver cancer	7.81e-06	3.3e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—liver cancer	7.78e-06	3.28e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—liver cancer	6.94e-06	2.93e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—liver cancer	6.77e-06	2.86e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—liver cancer	6.38e-06	2.7e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—liver cancer	5.11e-06	2.16e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—liver cancer	4.17e-06	1.76e-05	CbGpPWpGaD
